Inovio Pharmaceuticals calls its new vaccine INO-4800.
The vaccine is based on the DNA of the coronavirus but does not use the actual virus.
Forty adult volunteers will get two doses of the vaccine a month apart, with the first results by early summer.
Testing will be done at the University of Pennsylvania and in Kansas City.